Anesthesia Pharmacology: Renal Pharmacology
Acetazolamide (Diamox)
Glaucoma:
Decreases rate of aqueous humor production which leads to a declining in intraocular pressure
Most common indication for use of carbonic anhydrase inhibitors
Dorzolamide (Trusopf): topical carbonic anhydrase inhibitor.
No diuretic or systemic metabolic effects
Reduction in intraocular pressure comparable to oral agents
Urinary Alkalinization:
Increased uric acid and cystine solubility by alkalinizing the urine (by increasing bicarbonate excretion)
For prophylaxis of uric acid renal stones, bicarbonate administration (baking soda) may be required
Metabolic Alkalosis:
Results from:
Decreased total potassium with reduced vascular volume
High mineralocorticoid levels
These conditions are usually managed by treating the underlying causes; however, in certain clinical settings acetazolamide may assist in correcting alkalosis {e.g. alkalosis due to excessive diuresis in CHF patients}
Acute Mountain Sickness:
Symptoms: weakness, insomnia, headache, nausea, dizziness (rapid ascension of all of 3000 meters); symptoms -- usually mild
In serious cases: life-threatening cerebral or pulmonary edema
Acetazolamide (Diamox) reduces the rate of CSF formation and decreases cerebral spinal fluid pH.
Prophylaxis against acute mountain sickness may be appropriate
Other Uses:
Some role in management of epilepsy
Hypokalemia periodic paralysis
Increase urinary phosphate excretion during severe hyperphosphatemia.
Furosemide (Lasix), bumetanide (Bumex), torsemide (Demadex), ethacrynic acid (Edecrin)
Major Clinical uses:
Acute pulmonary edema
Acute hypercalcemia
Management of edema
Other uses:
Hyperkalemia:
Loop diuretics increase potassium excretion
Effect increased by concurrent administration of NaCl and water.
Acute renal failure:
May increase rate of urine flow and increase potassium excretion.
May convert oligouric to non-oligouric failure {easier clinical management}
Renal failure duration -- not affected
Anion overload:
Bromide, chloride, iodide: all reabsorbed by the thick ascending loop:
Systemic toxicity may be reduced by decreasing reabsorption
Concurrent administration of sodium chloride and fluid is required to prevent volume depletion.
Major Clinical Uses:
Hypertension
Congestive heart failure
Nephrolithiasis (due to idiopathic hypercalciuria)
Nephrogenic diabetes insipidus
Bendroflumethazide |
Benzthiazide |
Chlorothiazide (Diuril) |
Chlorthalidone (Hygroton) |
Hydrochlorothiazide (HCTZ, Esidrix, HydroDIURIL) |
Hydroflumethiazide |
Indapamide (Lozol) |
Methyclothiazide |
Metolazone (Zaroxolyn, Mykrox) |
Polythiazide |
Quinethazone |
Trichlomethiazide |
Mannitol (Osmitrol)
To increase urine volume:
May be used to prevent anuria if the kidney due to hemolysis or rhabdomyolysis is presented with a large pigmented load.
When renal hemodynamics are compromised
To decrease intracranial or intraocular pressure:
Mannitol extract water from intracellular compartments, reducing total body water
Following IV administration, intracranial pressure falls within 60-90 minutes.
Amiloride (Midamor), triamterene (Dyrenium), spironolactone (Aldactone)
Reduction of potassium loss associated with thiazide or loop diuretic administration
Mineralocorticoid excess:
Conn's syndrome (primary hypersecretion)
Ectopic ACTH production (primary hypersecretion)
Secondary aldosteronism caused by:
Congestive heart failure
Hepatic cirrhosis
Nephrotic syndrome
Conditions that cause renal salt retention with reduced intravascular volume
Other diuretics may further reduce intravascular volume thus worsening secondary aldosteronism
Cardiac glycosides |
Oral hypoglycemics |
Aminoglycoside antibiotics |
Uricosuric drugs |
Non-steroidal anti-inflammatory drugs |
Jackson, E.K. Diuretics In, Goodman and Gillman's The Pharmacological Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, pp. 685- 713
Jackson, E.K. Vasopressin and Other Agents Affecting the Renal Conservation of Water In, Goodman and Gillman's The Pharmacological Basis of Therapeutics, (Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, pp.715-732
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |